Kazia Therapeutics has in-licensed a novel SETDB1-targeted epigenetic drug platform from QIMR Berghofer, including the lead candidate MSETC, designed to restore immune response in treatment-resistant cancers. This acquisition expands Kazia's oncology pipeline to address tumor immune evasion at the chromatin level, complementing its existing therapies targeting gene expression and protein degradation. The SETDB1 program is in preclinical development with plans for IND-enabling studies and potential strategic partnerships. Kazia aims to advance this alongside its PD-L1 degrader program, with combined development costs estimated at $6 million over 18 months, supported by Australian R&D tax incentives.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
Amaroq Ltd. reported strong underground drilling results at the Nalunaq Gold Mine in Greenland, with high-grade gold intersections averaging 42.8 g/t Au, including some assays above 130 g/t Au. These results reinforce confidence in the mine's near- a...
